Pains and gains for cancer drugmakers ahead of industry meet

Harpoon Therapeutics

27/05/2022 16:30

(Updates)
    ** Shares of some cancer drug developers rally while others
trade in red on study data published ahead of key cancer
industry meet
    ** Shares of Iovance Biotherapeutics  IOVA.O  plunge over
50%, hitting their lowest since 2017 after company's skin cancer
therapy data disappoints  urn:newsml:reuters.com:*:nL3N2XJ1YU
    ** IOVA is the biggest pct loser on the Nasdaq Biotech index
 .NBI  and also leads biggest losers across major U.S. exchanges
    ** SpringWorks Therapeutics  SWTX.O  second biggest loser on
the biotech index; drops 40% after mixed cancer drug data
 urn:newsml:reuters.com:*:nL3N2XJ27M
    ** Mirati Therapeutics  MRTX.O  also ends up at the bottom
of the biotech index  urn:newsml:reuters.com:*:nL3N2XJ1QA
    ** Tempest Therapeutics  TPST.O , ImmunoGen  IMGN.O ,
Elevation Oncology  ELEV.O , Harpoon Therapeutics  HARP.O  among
other cancer drug developers in the red on data to be presented
at the ASCO meet in early June  urn:newsml:reuters.com:*:nL3N2XJ1TC
    ** On the flip side, PMV Pharmaceuticals  PMVP.O  is the
second biggest pct gainer on the NBI after reporting data on
experimental drug for solid tumors; Oncternal Therapeutics
 ONCT.O  shares also see boost  urn:newsml:reuters.com:*:nGNX7vTvxM  urn:newsml:reuters.com:*:nL3N2XJ1OM
    ** Merus NV  MRUS.O  also rallies on cancer antibody data;
up more than 20%, on course for biggest intraday pct gain since
October; Adicet Bio  ACET.O  ticks up on lymphoma therapy data
 urn:newsml:reuters.com:*:nL3N2XJ2FD  urn:newsml:reuters.com:*:nL3N2XJ1SH
    ** Exact Sciences  EXAS.O  and Cullinan Oncology  CGEM.O 
among other gainers 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))